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ALS-linked FUS exerts a gain of 
toxic function involving aberrant 
p38 MAPK activation
Reddy Ranjith K. Sama1, Claudia Fallini1, Rodolfo Gatto2, Jeanne E. McKeon1, Yuyu Song3,4, 
Melissa S. Rotunno1, Saul Penaranda4, Izrail Abdurakhmanov4, John E. Landers1, Gerardo 
Morfini2,4, Scott T. Brady2,4 & Daryl A. Bosco1
Mutations in Fused in Sarcoma/Translocated in Liposarcoma (FUS) cause familial forms of amyotrophic 
lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive axonal degeneration 
mainly affecting motor neurons. Evidence from transgenic mouse models suggests mutant forms of 
FUS exert an unknown gain-of-toxic function in motor neurons, but mechanisms underlying this effect 
remain unknown. Towards this end, we studied the effect of wild type FUS (FUS WT) and three ALS-
linked variants (G230C, R521G and R495X) on fast axonal transport (FAT), a cellular process critical 
for appropriate maintenance of axonal connectivity. All ALS-FUS variants impaired anterograde 
and retrograde FAT in squid axoplasm, whereas FUS WT had no effect. Misfolding of mutant FUS 
is implicated in this process, as the molecular chaperone Hsp110 mitigated these toxic effects. 
Interestingly, mutant FUS-induced impairment of FAT in squid axoplasm and of axonal outgrowth in 
mammalian primary motor neurons involved aberrant activation of the p38 MAPK pathway, as also 
reported for ALS-linked forms of Cu, Zn superoxide dismutase (SOD1). Accordingly, increased levels 
of active p38 MAPK were detected in post-mortem human ALS-FUS brain tissues. These data provide 
evidence for a novel gain-of-toxic function for ALS-linked FUS involving p38 MAPK activation.
Mutations in Fused in Sarcoma/Translocated in Liposarcoma (FUS/TLS or FUS) are causative for amyotrophic 
lateral sclerosis (ALS)1, 2, a progressive and fatal neurodegenerative disease characterized by progressive dying 
back degeneration of both upper and lower motor neurons3. Analysis of pathogenic mechanisms associated with 
mutant FUS in mammalian cells is complicated because FUS is a multifunctional protein engaged in numerous 
aspects of RNA and DNA processing, and overexpression of FUS WT proved cytotoxic3. Recent reports describ-
ing a series of transgenic FUS animal models provide strong evidence for mutant FUS exerting a gain-of-toxic 
function in the cytoplasm that results in motor neuron degeneration4–6. However, specific toxic function(s) 
associated with FUS mutations have not been elucidated, and could involve defects in RNA-related processes3, 
cytoskeletal transport7 and/or the proteostasis network8.
Deficits in fast axonal transport (FAT) and abnormal activation of protein kinases are early pathogenic events 
in both SOD1-related and sporadic forms of ALS9–15, but whether ALS-linked FUS affects FAT has not been eval-
uated. To address this issue, recombinant FUS proteins were perfused into isolated squid axoplasm and the effect 
on FAT examined. Although FUS WT had no discernable effect, ALS-FUS variants robustly inhibited anterograde 
(conventional kinesin-dependent) and modestly inhibited retrograde (cytoplasmic dynein-dependent) FAT when 
perfused into squid axoplasm. Irrespective of whether the disease-causing mutation affects the nuclear localiza-
tion signal (e.g., R521G or R495X) or the glycine-rich domain (e.g., G230C) of FUS, all disease variants tested 
similarly inhibited FAT. Addition of mutant FUS with the molecular chaperone Hsp110 mitigated this impair-
ment, suggesting that a misfolded conformation of mutant FUS underlies this gain-of-toxic function.
Pharmacological experiments further indicated that impairments in FAT in squid axoplasm and in axon out-
growth in murine primary motor neurons by mutant FUS both require activation of the p38 MAPK pathway, 
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which has been broadly implicated in various neurodegenerative disorders including Alzheimer’s Disease and 
ALS16–19. Indeed, aberrant activation of the p38 MAPK pathway by ALS-related forms of Cu, Zn superoxide dis-
mutase (SOD1) was previously demonstrated in squid axoplasm10, 12, 20 and transgenic mouse models expressing 
ALS-linked mutant SOD112, 21–23. We detected elevated levels of phosphorylated p38 MAPK in post-mortem 
CNS tissues derived from individuals harboring FUS mutations, providing support that the phenotypes observed 
in vitro in this report are relevant to the human disease. Although SOD1 and FUS have no known overlapping 
physiological functions, mutant and misfolded forms of these proteins appear to converge on a common path-
ogenic pathway that involves p38 MAP kinases. Together these results identify p38 MAPK activation as a novel 
gain of toxic function of mutant FUS that results in reductions in FAT and strengthens the association between 
the p38 MAPK axis and neurodegeneration in ALS.
Results
ALS-FUS inhibits fast axonal transport. Cytoskeletal abnormalities, including impaired axonal trans-
port, are implicated as early events in the pathogenesis of ALS and other neurodegenerative disorders24. We 
have demonstrated the utility of isolated squid axoplasm as a powerful ex vivo system to study alterations in FAT 
induced by disease-related neuropathogenic proteins10, 12, 20, 24–27, which were confirmed in mammalian disease 
models12 and in human post-mortem central nervous system (CNS) tissues10, 28, 29. Here, we sought to determine 
whether ALS-linked mutant FUS proteins also affect FAT in the squid axoplasm preparation. To this end, recom-
binant wild-type (WT) and three distinct ALS-linked FUS variants (G230C, R521G and R495X) were expressed 
and purified as glutathione-S-transferase (GST)-tagged recombinant proteins (Fig. 1A). Mutations R495X and 
R521G are located within a nuclear localization signal (NLS) that induce FUS translocation from the nucleus to 
the cytoplasm30, with R521 representing a “hot-spot” for ALS-linked FUS mutations31. The R495X truncation 
mutation leads to an omission of the entire NLS and a more aggressive disease phenotype (i.e., earlier age of onset 
and shorter disease duration) in affected patients30, 32. Conversely, mutations in the Gly-rich region of FUS, such 
as G230C, do not affect the cellular localization of exogenously expressed FUS in mammalian cells33. Because 
untagged FUS is intrinsically prone to aggregation34 and undergoes liquid-liquid phase separation35–38, the GST 
tag was maintained throughout this study to enhance the solubility of FUS proteins. Recombinant GST-FUS has 
been employed in various functional assays in vitro, and therefore the tag is not expected to disrupt the fold or 
function of this protein34, 39, 40. Moreover, the GST protein itself does not have an effect on FAT25.
Next, FUS proteins were perfused into squid axoplasm and their effect on FAT determined using 
video-enhanced contrast differential interference (DIC) microscopy27. The use of DIC microscopy in the axo-
plasm preparation allows for quantitation of anterograde (conventional kinesin-dependent) and retrograde (cyto-
plasmic dynein-dependent) transport of membrane-bounded organelles (MBOs) in real time27, 41. Because the 
plasma membrane is removed from the axon in a manner that leaves intact the FAT machinery and polarity of 
the axonal cytoskeleton, recombinant FUS proteins could be directly perfused into the axoplasm and their effect 
on FAT quantitatively measured27. Recombinant FUS proteins were perfused into squid axoplasm at 2.5 µM, a 
physiologically relevant concentration in mammalian cells38. Perfusion of FUS WT (2.5 µM) had no effect on 
either anterograde or retrograde FAT over the entire time course of the assay (50 min; Fig. 1B–D). In striking 
contrast, perfusions with either FUS G230C, R495X or R521G significantly inhibited anterograde FAT and, to a 
lesser extent, retrograde FAT (Fig. 1B,C,E,F,G). Together, these data reveal FAT inhibition as a novel, toxic gain of 
function for mutant FUS. Given the similar effect of all three variants tested, we focused our next experiments on 
FUS R521G, a mutation with high frequency in the ALS-FUS population31.
Inhibition of FAT by ALS-FUS is mediated by p38 MAPK. The inhibitory effect of mutant FUS pro-
teins on FAT was independent from nucleus-dependent activities (i.e., transcription) because neuronal cell bodies 
are absent from the axoplasm preparation41. Endogenous axoplasmic kinases and phosphatases are plausible 
candidates, as kinases mediate the inhibitory effect of other neuropathogenic proteins on FAT by promoting 
abnormal phosphorylation of conventional kinesin and cytoplasmic dynein, major molecular motors responsible 
for FAT in mature neurons. For example, activation of cJun N-terminal kinases (JNK) was found to mediate the 
inhibitory effect of pathogenic androgen receptor and huntingtin on FAT25, 26. Based on these precedents, we 
co-perfused the JNK-specific kinase inhibitor SP600125 with FUS R521G. However, inhibition of JNK did not 
rescue the inhibitory effect of mutant-FUS on FAT (Fig. 2A–C).
The beta-isoform of p38 mitogen-activated protein kinase (MAPK) also inhibits both anterograde and retro-
grade FAT in isolated squid axoplasm12, and ALS-related forms of ALS have been shown to inhibit FAT through 
a mechanism involving p38 activation10, 12, 20, prompting us to evaluate the potential role of this kinase. Strikingly, 
co-perfusion of FUS R521G with the p38 MAPK pharmacological inhibitor SB203580 completely prevented the 
adverse effects of this protein on FAT, restoring FAT rate values to that of control axoplasms (Fig. 2A,B,D). p38 
kinases are typically activated by sequential activation of upstream MAPK kinases (MKKs) and MAPK kinase 
kinases (MKKKs). An example of the latter is apoptosis signal-regulating kinases (ASKs), which mediates the 
inhibitory effects of pathogenic SOD1 variants on FAT20. Therefore, we assessed the effect of a pharmacological 
ASK1 inhibitor (NQDI-1) on FUS-mediated inhibition of FAT. Significantly, NQDI-1 also prevented the adverse 
effects of FUS R521G on FAT (Fig. 2A,B,E). Taken together, results from vesicle motility assays indicate that patho-
genic forms of two seemingly different ALS-linked proteins (FUS and SOD1) converge on a common pathway that 
involves aberrant activation of p38-specific MAP kinase pathways. There are, however, mechanistic differences 
between SOD1- and FUS-induced inhibition of FAT. Whereas both anterograde and retrograde FAT are impaired 
by mutant FUS (Figs 1 and 2), only anterograde FAT was significantly inhibited by misfolded SOD110, 12, 20. 
We previously detected phosphorylated p38 MAPK in squid axoplasm perfused with misfolded SOD1 by immu-
noblot analysis12. However, the same mammalian anti-p38 MAPK antibody used previously failed to detect acti-
vated p38 MAPK in squid perfused with mutant FUS (data not shown). These results suggest that different p38 
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MAPK isoforms may be activated by mutant FUS compared to misfolded SOD1, and that these different isoforms 
may not be detected by our available anti-phosphorylated p38 antibodies.
The molecular chaperone Hsp110 mitigates the effect of mutant FUS on FAT. Protein misfold-
ing is a hallmark feature of neurodegenerative diseases, including ALS8. Indeed, FUS aggregates are detected 
Figure 1. ALS-linked mutant FUS proteins impair anterograde and retrograde FAT. (A) ALS-linked mutations 
(G230C, R495X and R521G) investigated in this study are mapped onto the domain structure of GST-FUS. 
RRM = RNA recognition motif, RGG = arginine-glycine-glycine-rich, ZFD = zinc-finger domain and 
NLS = nuclear localization signal. (B–G) FUS proteins (2.5 μM) were perfused into isolated squid axoplasm 
and fast axonal transport (FAT) rates (μm/s) of membrane bounded-organelles measured as a function of time 
(minutes). For (B,C), slopes of the linear best fits for velocities obtained for each axoplasm (D–G) were averaged 
and plotted as bar graphs in Graphpad Prism with the standard error of the mean (SEM) for anterograde (blue 
bars; A) and retrograde (red bars; B) velocities. Those conditions with statistical significance (p < 0.05) relative 
to FUS WT are denoted by *, determined by one-way Anova and Tukey post-hoc test for multiple comparisons. 
(D–G) Motility plots comprised of the raw data for every axoplasm (‘n’ denotes the number of axoplasms 
analyzed for each condition) are shown, where linear best fits of the compiled data are shown for anterograde 
(blue arrowheads; linear fit shown as a solid blue line) and retrograde (red arrowheads; linear fit shown as a 
solid red line) directions. Protein obtained from at least two independent protein expression and purifications 
were included for each FUS variant.
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within neurons and glia of human post-mortem ALS-FUS tissue2, 42, in cultured cells1, and in vitro34. To address 
the possibility that a misfolded form of mutant FUS activates the p38 MAPK pathway, the molecular chaperone 
Hsp110 was co-perfused with mutant FUS protein. Hsp110 has been shown to stabilize unfolded proteins and 
synergize with other chaperones such as Hsp(c)70 and Hsp40 to disaggregate protein assemblies in vitro43, 44. 
Specifically, Hsp110 prevented mutant SOD1 from activating p38 MAPK in axoplasm20 and overexpression of 
Hsp110 extended the survival of mutant SOD1 transgenic mice45. Co-perfusion of substoichiometric amounts of 
Hsp110 to FUS R521G (1:4) significantly attenuated the inhibitory effect of mutant-FUS on both anterograde and 
retrograde FAT rates, which were similar to those observed in FUS WT-perfused axoplasms (Fig. 2A,B,F). These 
data suggest that a misfolded conformation of mutant-FUS may underlie its inhibitory effect on FAT20.
Next, we attempted to identify the putative misfolded mutant FUS species. Recombinant FUS protein stocks 
used for squid axoplasm studies were analyzed using electron microscopy (EM). There was no visible protein 
precipitate, nor were any proteins in a hydrogel-like state. Instead, EM images revealed a mixture of oligomeric 
Figure 2. The inhibitory effect of mutant-FUS on FAT is mediated by activated p38 MAPK. FUS R521G was co-
perfused with the indicated pharmacological inhibitor or Hsp110 into squid axoplasm and fast axonal transport 
evaluated as described in Fig. 1. (A–C) Co-perfusion of the pharmacological JNK kinase inhibitor SP600125 
(0.5 μM) with R521G failed to rescue FAT inhibition. In contrast, inhibition of the p38 MAPK pathway by 
co-perfusion of either SB203850 (5 μM) or NQDI-1 (20 μM) prevented the toxic effects of FUS R521G on FAT 
(A,B,D,E). (F) Similarly, co-perfusion of Hsp110 (0.6 μM) and R521G ameliorated the inhibition of FAT by 
mutant FUS. Those conditions with statistical significance (p < 0.05) relative to FUS R521G are denoted by *, 
determined by one-way Anova and Tukey post-hoc test for multiple comparisons.
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and higher-ordered protein assemblies for both FUS WT (Fig. 3A) and mutant FUS proteins (Fig. 3B–D). This 
morphological heterogeneity precluded the identification of a specific mutant FUS species that would trigger the 
defects in FAT.
Inhibition of p38 MAPK rescues impaired axon outgrowth in mammalian motor neurons 
expressing mutant FUS. Axonal defects have been reported in cortical neurons ectopically expressing 
mutant FUS46, and endogenous expression of mutant FUS in motor neurons derived from patient iPSCs reca-
pitulated ALS-relevant phenotypes such as hyperexcitability47. Here, we sought to determine whether mutant 
FUS-induced toxicity within mammalian motor neurons involves p38 MAPK activity as demonstrated for 
squid axoplasm (Figs 1 and 2). To this end, murine motor neurons were transiently transfected at day in vitro 
(DIV) 2 with FLAG/HA-FUS WT, R521G and P525L in the presence of either MW069 (20 μM), an inhibitor 
with higher selectivity for p38 MAPK than SB203580, or a structurally related, inactive analogue of MW069 
(MW069_inactive, 20 μM) as a negative control48. Motor neurons were co-transfected with the green fluorescent 
protein (GFP) to facilitate visualization of axonal outgrowth using live cell imaging (Fig. 4A and Supplemental 
Video S1). In the presence of MW069_inactive, axon outgrowth was significantly impaired in motor neurons 
expressing FUS P525L compared to those expressing FUS WT (Fig. 4B,C). Strikingly, axonal outgrowth rates 
in FUS P525L expressing motor neurons were restored to WT FUS levels in the presence of the active MW069 
inhibitor (Fig. 4B,C). Axon outgrowth speed was also reduced in FUS R521G expressing motor neurons treated 
with MW069_inactive, although this reduction was not statistically significant compared to FUS WT with 
MW069_inactive treatment (p = 0.32). Moreover, the active MW069 inhibitor had no effect on axon outgrowth 
speed in FUS R521G expressing motor neurons (Fig. 4C). These latter results are suggestive of a toxic function 
of FUS R521G within the nucleus, where this protein is predominately expressed within intact motor neurons, 
that is unrelated to p38 MAPK activation (Fig. 4A). Supporting this idea, FUS P525L is severely mislocalized to 
the cytoplasm33 and expressed at detectable levels within the axon (Fig. 4A). Analogous to the direct perfusion of 
mutant FUS proteins into squid axoplasm (Figs 1 and 2), the presence of mutant FUS within axons of intact motor 
neurons was sufficient to induce toxicity through a mechanism involving p38 MAPK activity. Importantly, the 
MW069 inhibitor also rescues the inhibition of FAT by mutant FUS in squid axoplasm (Fig. 4D).
Increased activation of p38 MAPK is detected in human post-mortem ALS tissue. To evaluate 
the disease relevance of findings in the squid axoplasm preparation, we investigated the relationship between 
mutant FUS expression and p38 MAPK activation in nerve tissue samples obtained from ALS-FUS cases. 
Specifically, we examined post-mortem CNS tissues derived from ALS individuals harboring different FUS 
Figure 3. The morphology of FUS species assessed by electron microscopy. Representative electron microscopy 
(EM) images of negatively stained FUS WT (A), G230C (B), R521G (C) and R495X (D) proteins. Low 
magnification images are shown in the top row (scale bar represents 0.5 μm). High magnification images are 
shown for insets (dashed squares) in the bottom row (scale bar represents 200 nm). FUS exhibits heterogeneous 
morphologies across all samples.
www.nature.com/scientificreports/
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mutations (Supplemental Table S2), including R521G, H517Q, a splice site mutation (ex14del) that causes skip-
ping of exon14, P525L and a base pair deletion (bp1408del) (A1-A5, respectively, in Fig. 5). Both ex14del and 
bp1408del are predicted to cause a frame shift, resulting in FUS proteins comprised of 477 and 526 amino acids, 
respectively, but without the correct FUS sequence at the C-terminus. All cases exhibited both upper and lower 
motor neuron pathology at autopsy (Supplemental Table S2), consistent with FUS pathology reported in both 
motor cortex and spinal cord (SpC) tissues42.
Next, we evaluated p38 MAPK activation in post-mortem brain and SpC tissues by immunoblotting using an 
antibody that selectively recognizes catalytically active forms of p38 (p-p38) phosphorylated by upstream MKKs. 
A phosphorylation-independent antibody against p38 MAPK (total p38) served as internal control for expression 
and loading. An anti-GAPDH antibody served as an additional loading control for each analysis. Notably, when 
compared to control tissues there were elevated levels of p-p38 relative to total p38 MAPK in both ALS motor 
cortex (Fig. 5A) and SpC (Fig. 5B) tissues, with a more pronounced effect in brain samples than in SpC. Three 
out of five ALS cases (A2-4) expressed elevated levels of p-p38 in tissue derived from the motor cortex (Fig. 5A), 
with p-p38 levels above the mean of the control set (Fig. 5C). Additional immunoblot analyses were performed on 
the brain samples. For example, a qualitative direct correlation between p-p38 and p-Hsp27, a target of p-p3849, 
provided independent evidence of increased p38 activation in these samples (Fig. 5A). Interestingly, three of 
the five ALS cases (A1, A3 and A4), all expressing mutant forms of FUS that are expected to exhibit cytoplasmic 
mislocalization1, 30, 33, express relatively high levels of FUS (Fig. 5A,D). This trend is consistent with the notion 
Figure 4. Mutant FUS impairs axon outgrowth in motor neurons through a mechanism involving p38 MAPK 
activity. Murine motor neurons were transiently co-transfected with FLAGHA-FUS WT, R521G or P525L and 
green fluorescent protein (GFP) at 2 days in vitro (DIV). Motor neurons were cultured in 20 μM MW069, a 
potent and selective p38 MAPK inhibitor, or an inactive analogue, MW069_inactive. (A) FUS WT and R521G 
are predominately expressed within the nucleus of motor neurons, where as FUS P525L is expressed in the 
nucleus and within axons (white arrowheads). FUS P525L localization is similar whether motor neurons are 
treated with MW069_inactive or MW069 (+MW069). (B) Montages corresponding to live cell imaging of axon 
outgrowth (white arrow) over a 60 min time course for the indicated condition. Note that the growth cone of a 
FUS P525L expressing motor neuron is stalled in the presence of MW069_inactive (middle panel) relative to 
the active form of MW069 (bottom panel). See Supplemental Video S1 for live cell imaging of all conditions. 
(C) Quantification of axon outgrowth speed compiled from n = 3 biological experiments normalized to the 
WT + MW069_inactive condition. Statistical significance (**p < 0.01) of pertinent comparisons are indicated. 
Additional significant comparisons include FUS WT + MW069 versus FUS R521G + MW069_inactive 
(p < 0.05) and FUS WT + MW069 versus FUS P525L + MW069_inactive (p < 0.0001). (D) The inhibition of 
FAT by FUS R521G is blocked by MW069 in squid axoplasm. The motility plot for FUS R521G in the absence of 
MW069 is shown in Fig. 1G.
www.nature.com/scientificreports/
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that mislocalized FUS fails to properly autoregulate its expression50. Two FUS bands were detected in the immu-
noblot for A3, the ALS case with the highest FUS levels; the faster migrating band is attributed to the mutant 
(477 amino acids) form, whereas the slower migrating protein (526 amino acids) is produced from the wild-type 
allele (Fig. 5A). The differences between control and ALS did not reach statistical significance for p-p38 (Fig. 5C; 
p = 0.16) or FUS (Fig. 5D; p = 0.053) biochemical quantification, likely due to the relatively small number of 
human cases that were available for this study and the inherent variability of human postmortem tissue, but the 
trend was consistent with increased p-p38 levels.
Paraffin-fixed motor cortex tissue was available for a subset of our ALS (A2 and A3) and control (C3 and C12) 
cases that could be used for immunostaining. Consistent with results from the immunoblot analysis, immunos-
taining of motor cortex tissue revealed higher p-p38 immunoreactivity from ALS cases, compared to control 
cases (Fig. 6). Tissues were co-stained with SMI31, an antibody reactive for phosphorylated neurofilament H that 
can be used to assess neuroaxonal integrity51. As expected from the marked degeneration of neurites that charac-
terizes ALS pathology52, SMI31 reactivity was markedly reduced in both ALS cases compared to controls (Fig. 6 
and Supplemental Figure S3). Quantification of the ratio of p-p38 to SMI31 revealed a statistically significant 
difference between controls (0.044 +/− 0.010) and ALS (0.243 +/− 0.017, p < 0.0001; Supplemental Figure S4). 
Figure 5. Increased levels of phosphorylated p38 MAPK in human post-mortem CNS tissues derived from 
individuals with ALS-FUS. Immunoblot analysis of frozen post-mortem brain (A) and spinal cord (B) tissues 
derived from non-disease control (C1-C11) and ALS individuals harboring FUS mutations (A1-R521G; A2-
H517Q; A3- ex14del; A4-P525L and A5- bp1408del) with the indicated antibodies (see Supplemental Table S2 
for detailed patient information). (C) Quantification of phosphorylated (active) p38 (p-p38) by immunoblot 
analysis revealed higher levels of p-p38 MAPK in ALS cases (cases with levels above the control mean are 
indicated by red squares), compared to control cases. P-p38 values were normalized to total p38 levels. (D) 
Quantification of FUS levels in brain normalized to Gapdh. ALS cases with FUS levels above the control mean 
are indicated by red squares. (C,D) Although, there appears to be a trend in the data, differences between ALS 
cases and controls did not reach statistical significance due to the small sample size and inherent variability of 
human postmortem samples.
www.nature.com/scientificreports/
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Elevated levels of phosphorylated p38 MAPK in affected ALS-FUS tissues shown here are consistent with reports 
of elevated p38 MAPK in SOD112, 22, 53 and sporadic16 forms of ALS.
Discussion
The identification of mutant FUS-specific phenotypes have been elusive, in part because FUS WT overex-
pression elicits a toxic phenotype in many model organisms34, 54–56. Important insights into the mechanism of 
FUS-mediated pathogenesis were recently revealed by two independent studies, which compared FUS knockout 
mice to a series of transgenic mouse lines expressing the human FUS transgene at or below endogenous FUS 
levels4, 5. Both studies demonstrated that a loss of FUS expression does not cause motor neuron degeneration, 
whereas cytoplasmic mislocalization of FUS due to deletions or point mutations within the nuclear localization 
signal induced age-dependent, motor neuron degeneration4, 5. Collectively, these in vivo studies strongly impli-
cated a toxic gain of function mechanism in FUS-mediated ALS pathogenesis. However, specific toxic effects of 
mutant FUS in the cytoplasm remained unknown. The present study using isolated squid axoplasm sheds new 
light on this question, as we demonstrate that mutant, but not WT forms of FUS, impair FAT through a mecha-
nism dependent on activation of p38 MAPK (Fig. 7).
Axonal transport defects are a common pathological feature of neurodegenerative disorders24, and represent 
an early, pre-symptomatic event in motor neuron diseases including familial and sporadic forms of ALS24, 57. 
Evidence in humans and ALS transgenic model organisms support a ‘dying back’ pattern for motor neuron death 
that is initiated by pathogenic events within the distal axon, including the breakdown of neuromuscular junc-
tions (NMJs)11, 57. Consistent with a common disease phenotype associated with different genetic causes of ALS, 
dysfunctional NMJs preceded the loss of neuronal cell bodies in mutant FUS mice5. Transient expression of the 
cytoplasmically mislocalized FUS P525L variant resulted in reduced axon outgrowth in primary motor neurons 
(Fig. 4), consistent with observations of abnormal axonal morphologies in primary cortical neurons expressing 
mutant FUS46. In addition, recent work using Drosophila larval motor neurons reported a reduction in antero-
grade transport of MBOs induced by both WT and the cytoplasmically mislocalized P525L mutant FUS variant58. 
While physiologically relevant concentrations of FUS WT did not affect FAT in isolated axoplasm (Figs 1 and 2), 
the Drosophila study involved overexpression of FUS, which in some cases can cause toxicity34, 54–56. The effects 
of FUS WT on FAT in Drosophila may also represent an epiphenomenon of FUS-modulated changes in gene 
expression or other nuclear activities3, 59. Supporting this view, a trend toward reduced axon outgrowth speed was 
observed in motor neurons expressing the predominately nuclear FUS R521G variant (Fig. 4), but this effect was 
not mitigated by p38 MAPK inhibition as observed for the predominantly cytoplasmic FUS P525L mutant variant 
(Fig. 4). Additional work is needed to evaluate the extent to which nuclear dysfunction-specific mechanisms of 
FUS contribute to FAT alterations and impaired axon outgrowth within intact neurons.
Unlike other models, isolated squid axoplasm affords a unique, ex vivo experimental system to directly com-
pare the effects of FUS WT and ALS-linked variants because proteins are perfused directly into axoplasm at the 
Figure 6. Active p38 MAPK in neurons within post-mortem motor cortex tissues from individuals diagnosed 
with ALS-FUS. Brain sections from paraffin-embedded tissue samples obtained from two control (C3 and C12) 
and two ALS-FUS (A2 and A3) cases were probed with antibodies against phosphorylated, catalytically active 
p38 (P-p38; red), phosphorylated neurofilament H (SMI31; green) as a marker of neuroaxonal integrity, and the 
nuclear stain DAPI (blue). Scale bar represents 10 μm. Low magnification images are shown in Supplemental 
Figure S3. The P-p38 signal is higher, and SMI31 signal lower, in both ALS cases compared to controls; see 
Supplemental Figure S4 for quantification.
www.nature.com/scientificreports/
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same concentrations. Regardless of whether these variants are predominately expressed in the nucleus (G203C), 
cytoplasm (R495X), or somewhere in between (R521G) within intact cells, they all inhibited FAT to a similar 
extent, implicating a common toxic feature among FUS mutants. The protective effect of Hsp110 (Fig. 2) further 
raised the possibility that a misfolded conformation underlies the toxic effect of mutant FUS on FAT. Hsp110 is 
nucleotide exchange factor for Hsp(c)70, and together with Hsp40 these chaperones comprise a mammalian dis-
aggregase system that dissolves amorphous protein aggregates in vitro43, 44. FUS variants are known to aggregate 
in vitro and in vivo34, although FUS aggregation is not required to induce motor neuron degeneration in vivo4, 5. 
Interestingly, FUS has been shown to undergo liquid-liquid phase separation and assemble into a hydrogel35–38. 
Here, all FUS samples were soluble (i.e., not visibly precipitated or in a hydrogel-like state) before they were 
perfused into squid axoplasm or subjected to EM. Nonetheless, EM analysis revealed the presence of soluble, 
self-associated FUS species in both FUS WT and mutant FUS samples (Fig. 3), precluding our ability to assign the 
‘toxic’ FUS species to a particular size or morphology of FUS aggregate, as reported for other neuropathogenic 
proteins60. Our studies do not exclude the possibility that mutant FUS proteins acquire a toxic conformation 
within the squid axoplasm, but this possibility is difficult to investigate with current methods. Further, recombi-
nant FUS is largely disordered, precluding structural analyses of the isolated full-length protein3. Thus, confor-
mational properties of mutant FUS that confer toxicity await further study.
Inhibition of FAT by mutant FUS occurs through a mechanism that involves activation of the p38 MAPK 
pathway (Fig. 2). Active p38 MAPK was previously shown to phosphorylate and inhibit kinesin-1 subunits of 
conventional kinesin, providing a mechanistic basis by which p38 MAPK activation impairs FAT12. FUS overex-
pression was recently correlated with glycogen synthase kinase 3β (GSK-3β) kinase activation, which also affects 
anterograde FAT61, although this effect was not mutant-specific62. Nonetheless, these observations support the 
notion that disease-causing neuropathogenic proteins may exert toxicity through inappropriate activation of 
kinase-signaling cascades. Although our studies evaluate axon-autonomous effects, mutant forms of FUS and 
SOD1 would likely affect other p38 MAPK-related processes within intact mammalian neurons in vivo, including 
but not limited to transcription and activation of apoptotic pathways (Fig. 7). Intriguingly, ALS-linked forms of 
SOD1, a functionally and structurally dissimilar protein compared to FUS, similarly impaired FAT in squid axo-
plasm through activation of a p38 MAPK pathway10, 12, 20. In fact, multiple groups12, 21–23 have reported increased 
levels of active p38 MAPK in the SOD1-G93A transgenic ALS mouse model, as well as in human sporadic and 
familial ALS forms16, 18. Here, we detected elevated levels of phosphorylated p38 MAPK in the motor cortex of 
human ALS-FUS cases (Figs 5 and 6). Increased levels of active p38 MAPK in disease models of different ALS 
Figure 7. Model for aberrant activation of p38 MAP kinase(s) by mutant and misfolded ALS-associated 
proteins. Available data (from this study and others10, 12, 20) support a model whereby mutant and misfolded 
forms of FUS (mFUS; left) and SOD1 (mSOD1; right) induce the aberrant activation of the p38 MAPK pathway. 
Hsp110 likely synergizes with other chaperones to ameliorate the effects of mSOD1 and mFUS, possibly 
upstream of ASK1 and additional unidentified factors. While mSOD1 and mFUS converge on p38 MAPK 
activation, perfusion of these proteins into squid axoplasm have differential effects on FAT; mFUS inhibits both 
anterograde (←) and retrograde (→) FAT (Figs 1 and 2) whereas mSOD1 only inhibits anterograde FAT10, 12, 20,  
consistent with inhibition of the beta and alpha isoforms of P38 MAPK, respectively12. In addition to FAT 
inhibition in squid (solid lines), mFUS- and mSOD1-induced activation p38 MAPK can manifest different 
phenotypes in mammalian systems (dashed lines), including but not limited to inhibition of axon outgrowth 
(Fig. 4) and enhanced susceptibility to cell stress12. This figure is adapted from Song et al.20.
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variants suggests that specific molecular components within the p38 MAPK axis may represent viable therapeu-
tic targets to treat ALS19. Indeed, inhibition of p38 MAPK activity using poorly penetrant inhibitors correlates 
with improved motor neuron survival in ALS-SOD1 transgenic mice22, 53. The development of highly specific, 
brain-penetrant MAPK inhibitors should facilitate a better evaluation of p38 MAPK contributions to ALS-related 
phenotyopes in vivo19. Collectively, findings in this work provide a novel conceptual framework for the develop-
ment of therapeutic strategies aimed to prevent the adverse consequences of p38 MAPK activation in ALS and 
other neurodegenerative disorders.
Materials and Methods
Recombinant FUS expression and purification. FUS WT, R521G, R495X or G230C constructs were 
cloned into pGEX-6P1 vector (GE Life Sciences) and expressed in Rosetta DE3 cells (Novagen) as follows. Single 
bacterial colonies were inoculated into 5 ml growth medium (luria broth with 100 µg/ml ampicillin and 34 µg/ml 
chloramphenicol) and incubated at 37 °C while shaking for 8 h, after which these cultures were used to inocu-
late 150 ml growth medium (intermediate culture) that was then incubated at 30 °C for ~24 h. The intermediate 
cultures were used to inoculate 2L growth medium to an OD600 of 0.1–0.2. Cultures were grown at 20 °C until 
an OD600 ~0.8, at which time IPTG (Isopropyl β-D-1-thiogalactopyranoside) and ZnCl2 were added to a final 
concentration of 150 µM and 50 µM, respectively, and cells were grown for an additional 22 h at 20 °C. Cells were 
harvested by centrifugation and cell pellets were resuspended in lysis buffer (50 mM Tris pH 8.0 with 1 mM 
Dithiothreitol (DTT), 0.1 mM Ethylenediaminetetraacetic acid (EDTA) and protease inhibitor cocktail (Roche)). 
Cells were lysed by sonication on ice in the presence of 10 µg/ml RNase A. GST-fusion proteins were purified 
from cleared lysates with Glutathione-Agarose (Sigma, #G4510) resin according to the manufacturer’s instruc-
tions and stored at −80 °C.
Squid axoplasm vesicle motility assays. Vesicle motility assays were performed as described previ-
ously12, 20, 27. GST-FUS proteins alone or in combination with either pharmacological inhibitors or Hsp110 pro-
tein were employed at the following final concentrations: 2.5 µM GST-FUS proteins, 5 µM of SB203580 (EMD 
Millipore; 55-938-91MG), 0.5 µM of SP600125 (EMD Millipore; 42-011-95M), 10 µM of MW-069 (a gift from Dr. 
M. Watterson, Northwestern University), 20 µM NQDI1 (R&D Systems; 4429) and 0.6 µM HSP110 (a gift from 
Dr. A. Horwich, Yale University). FAT rates shown in Figs 1 and 2 were plotted using Prism (GraphPad software). 
The slope of the linear best-fit line for each individual axoplasm was calculated and the mean of slopes for each 
condition was plotted as bar graphs using Prism.
Transmission Electron Microscopy. Samples (10 µl) containing purified 12.5 µM GST-FUS protein was 
adsorbed onto a carbon stabilized, Formvar support film applied to a 200 mesh copper grid for 30 seconds. The 
grids were then washed with water and negatively stained with 1% aqueous uranyl acetate in water as described63. 
The stained grids were analyzed using a Philips CM10 transmission electron microscope and images were cap-
tured at both low (20,500X) and high (87,000X) magnification using a Gatan Erlangshen 785 CCD digital camera 
system.
Axon outgrowth measurements in primary motor neurons. Motor neurons were isolated from 
embryonic (E)12.5 mouse embryos and cultured as described64. FLAGHA-FUS expression cassette vectors were 
generated from pFRT-TO-DEST-FLAGHA-FUS-WT, which was obtained from Addgene (#26373). ALS-linked 
mutations were introduced with the QuikChange II Mutagenesis kit (Stratagene; 200523) according to the man-
ufacturer’s instructions. Cells were transfected at 2 days in vitro (DIV)65 with green fluorescent protein (GFP) 
and FLAGHA-tagged FUS constructs in a 1:2 ratio with NeuroMag (OZ Biosciences) as previously described65. 
FLAGHA-FUS plasmids were generated from pFRT-TO-DEST-FLAGHA-FUS-WT obtained from Addgene 
(#26373). The QuikChange II Mutagenesis kit (Stratagene; 200523) was used to introduce the R521G and P525L 
mutations according to the manufacture’s instructions. Twenty µM MW069 or its inactive form (MW069_inac-
tive) were added to the culture medium after transfection to inhibit p38 activity48 and maintained throughout the 
experiment for a total of ~18–24 hours. Cells were imaged at 3 days in vitro (DIV) using a Nikon TiE widefield 
microscope equipped with temperature- and CO2-controlled environmental chamber. Neurobasal medium was 
replaced with Hybernate E Low Fluorescence (BrainBits) 1 hour prior to imaging to reduce autofluorescence and 
light toxicity. GFP was used to identify transfected cells. Movies were acquired with a 20x lens at a rate of 1 frame 
every 10 minutes for 1 hour. The speed of axon outgrowth was measured using the ImageJ plugin MTrackJ66, 67. 
Data from three independent, biological replicates were normalized to the condition with FUS WT in the pres-
ence of MW069_inactive. Statistical analysis (2-way ANOVA followed by Tukey’s multiple comparisons test) 
was performed using Graph Pad Prism 6 to establish statistical differences (p < 0.05) between conditions. To 
assess FLAGHA-FUS expression, cells were post-fixed in 4% paraformaldehyde for 15 minutes and stained with 
an anti-HA antibody (Cell Signaling - C29F4; 1:500) overnight at 4 °C. Secondary antibody (donkey anti-Rabbit 
conjugated with Alexa594; Jackson ImmunoResearch) was incubated at room temperature for 1 hour.
Processing of post-mortem tissues. Frozen post-mortem tissues were a generous gift from Dr. Robert 
H. Brown, Jr. (University of Massachusetts Medical School). Frozen tissue samples (~100 mg) were transferred 
to 2 mL borosilicate glass tube (Wheaton, #358028) containing lysis buffer (50 mM Tris–HCl (pH 7.5) supple-
mented with 0.5 M NaCl, 1% NP-40, 1% deoxycholic acid, 0.1% SDS, 2 mM EDTA, protease and phosphatase 
inhibitors (Roche)). Tissues were homogenized at 4 °C using a motorized tissue grinder with motor (Wheaton,) 
and the resulting lysates cleared by centrifugation prior to total protein determination using a bicinchonic acid 
(BCA) based colorimetric assay (ThermoScientific). Thirty micrograms of total protein was loaded onto gels for 
SDS-PAGE and immunoblot analyses. The following antibodies were employed: anti-phospho-p38 MAPK (Cell 
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Signaling, #9215), anti-total-p38 MAPK (Sigma, #M0800) and anti-GAPDH (Sigma, #G8795). Densitometry was 
performed using the Odyssey infrared imaging systems software (LI-COR).
Paraffin embedded tissues were acquired through the Alzheimer’s Disease Research Center at the Massachusetts 
General Hospital (Charlestown, MA). Paraffin was removed using progressive dilutions of alcohol and Xylene 
as described68. Tissue sections were permeabilized with 0.2% Triton-X-100 in TBS and blocked with TBS plus 
2.5% goat serum (Sigma-Aldrich, G9023). Primary antibodies used were anti-phospho p38 MAPK (P-p38) (Cell 
Signaling CS#4511; 1:200) and SMI-31 (Covance SMI-31R, 1:1000). Secondary antibodies were goat anti-rabbit 
Alexa 647 serum (Invitrogen, A21244) and goat anti-mouse Alexa 488 serum (Invitrogen, A21235), both used 
at a 1:1000 dilution. Slides were dried and mounted using Dapi Fluoromont-G (SoutherBiotech) hard mounting 
media. Images were acquired using an LSM-710 confocal microscope (Zeiss). For quantitative immunofluores-
cence analysis, images corresponding to five regions of interest (ROIs) per case were acquired from motor cor-
tex using the same settings. Ten images (2 cases × 5 ROIs) gathered from each channel (647 nm for P-p38 and 
488 nm for SMI-31 antibodies, respectively) were processed and average pixel counts determined using standard 
auto-threshold algorithms embedded in ImageJ software (http://imagej.nih.gov/ij/). Statistical analysis (unpaired 
student t -test) with Graph Pad Prism 6 (La Jolla, CA) was used to establish statistical differences (p < 0.05) 
between control versus ALS-FUS cases. All procedures were repeated twice with similar results.
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